Background: Previous studies have shown that calcium channel blockers can cause cutaneous adverse reactions; however, the amounts of data collected are limited. Recently, there have been new drugs available for which only a few reports have been published with regard to cutaneous adverse reactions.
Introduction
Calcium channel blockers (CCBs) are frequently used to treat cardiovascular diseases such as hypertension. 1 These drugs can be classified into several subgroups, based on receptor binding properties, tissue selectivity, and pharmacokinetic profiles. However, only three main subgroups, dihydropyridine (eg. nifedipine, nimodipine, felodipine, manidipine, and amlodipine), benzothiazepine (eg. diltiazem), and phenylalkylamine (eg. verapamil) are widely used in clinical treatment. 2 Both allergic and non-allergic adverse drug reactions (ADRs) have been reported, such as flushing, gingival hyperplasia, gynaecomastia and also cutaneous ADRs. 3, 4 Serious adverse events such as anaphylaxis, Steven-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have occasionally been reported. [3] [4] [5] [6] However, previous studies of CCBinduced cutaneous ADRs are limited, and most of them are case reports. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Recently, there have been new drugs available on the market, such as amlodipine and manidipine, and only a few reports have been published about cutaneous ADRs from these new drugs. Therefore, the purpose of our study weas to estimate the rate and to study updated clinical patterns of cutaneous ADRs to CCBs, including amlodipine and manidipine.
Methods
Patients who had cutaneous ADRs to CCBs were reported to the Adverse Drug Reaction (ADR) Center by attending physicians and dermatologists. Well-trained and experienced ADR Center pharmacists and dermatologists then reviewed the event and assessed the culprit drugs, based on history, clinical manifestations, and investigations. The culprit drugs in the cases were classified into 6 levels (certain, probable, possible, unlikely, unclassified, and unclassifiable) according to World Health Organization-Uppsala Monitoring Centre (WHO-UMC) Categories. 19, 20 Patients 18 years of age and above, who had cutaneous ADRs to CCBs and were reported to the ADR center from January 2004 to December 2010 at Faculty of Medicine Siriraj Hospital, a medical school and a tertiary referral center in Thailand, were enrolled. This study was approved by the Siriraj Institutional Review Board, Mahidol University.
Statistical analysis
Descriptive statistics were used for demographic data, underlying diseases, previous drug allergies, and characteristics of cutaneous ADRs. All statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL).
Results
During the six-year period, there were 996,583 prescriptions of CCBs in Siriraj Hospital but only 46 patients (48 times) developed cutaneous ADRs; the rate was thus 48 per million prescriptions. All except one of the patients were Thai. The other was Chinese. Females were more likely to develop Table 2 .
According to WHO-UMC Guidelines, 19,20 17 patients (37%) were diagnosed as probable ADRs and 29 patients (63%) were diagnosed as possible ADRs. No patient was diagnosed as having a certain reaction to CCBs due to concern about doing challenge testing. After excluding anaphylaxis that caused the reactions occurring within 2 hours of CCBs administration, the mean duration of developing cutaneous ADRs was 14.6 days (range, 1-111 days, SD±21.6 days). The rates of cutaneous ADRs to CCBs per million prescriptions are shown in Table 3 . The most common dermatologic manifestation was maculopapular rash (41.7%) caused by amlodipine, diltiazem, and manidipine, respectively. The second most common cutaneous ADRs was ankle/pedal edema (18.8%) which was caused by amlodipine, manidipine, and nifedipine, respectively. Although less common, CCBs can also cause severe skin reactions in some individuals. Three patients (6.2%) developed SJS due to amlodipine (possible ADR). One patient (2.1%) developed TEN due to manidipine (possible ADR) ( Table 4) .
Nine patients (18.8 %) were admitted due to their adverse drug reactions and had life threatening conditions ie anaphylaxis, SJS or TEN. All patients survived and made a full recovery without lasting severe adverse effects. Four patients (8.7%) had systemic involvement which was renal or cardiovascular. All of them showed full recovery.
Discussion
Previous studies of ADRs associated with antihypertensive drugs have shown that CCBs were the most common cause of ADRs, followed by diuretics and -blockers. 21 In this study, we focused on CCB-induced cutaneous ADRs. Females appear more likely than males to develop drug reactions, which is similar to other published data. However, the mechanism is not clear. [21] [22] [23] Previous reports suggest that pedal edema is the most common cutaneous ADR (up to 30%). 3, 7 Many mechanisms have been proposed in order to explain pedal edema, such as fluid-volume retention, effects on the reninangiotensin-aldosterone system and precapillary arteriolar vasodilatation. 3, 24 In this study, only 18.8% of our patients developed pedal edema, less than those who developed maculopapular rash. This may be due to cases being under-reported to the ADR Center. In our study, the rate of diltiazem-induced cutaneous ADRs is highest (91.3 cases per million prescriptions) compared to a previous study that indicated that verapamil is the most common cause (16.6 cases per million prescriptions). The previous study did not include amlodipine because amlodipine was approved by the U.S Food and Drug Administration until after their publication. 4 (Table  5 ) Amlodipine-induced cutaneous ADRs were reported in 21 patients. Because amlodipine was prescribed more frequently than other medications, calculation including the number of prescriptions showed that the rate of amlodipine-induced . In addition, it should be noted here that we had only a small number of patients who were receiving nimodipine. (Table 2 ) Even though ADRs from CCBs were infrequent, our study has shown that these drugs can occasionally cause severe adverse cutaneous ADRs. Considering amlodipine-induced SJS and manidipine-induced TEN, the rates were 7.1 and 5.5 cases per million amlodipine-, and manidipineprescriptions, respectively. To the best of our knowledge, there has been only one case of amlodipine-induced SJS reported previously and one case report of amlodipine-induced TEN. There were no reports of manidipine-induced severe cutaneous ADRs.
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Conclusions
Despite enrolling many patients who received CCBs, only a few of them developed cutaneous adverse reactions. In addition, it is important to keep in mind that some patients may develop serious skin reactions from CCBs. The limitation of this study is the small sample size of CCBs-induced cutaneous adverse reactions in spite of the large unber of prescriptions.
